Skip to main content

Peer Review reports

From: Rapid initial decline in BCR-ABL1 is associated with superior responses to second-line nilotinib in patients with chronic-phase chronic myeloid leukemia

Original Submission
23 Aug 2012 Submitted Original manuscript
19 Sep 2012 Reviewed Reviewer Report - Rainer Spang
21 Sep 2012 Reviewed Reviewer Report - Anja von Heydebreck
13 Nov 2012 Author responded Author comments - Andrew Stein
Resubmission - Version 2
13 Nov 2012 Submitted Manuscript version 2
30 Nov 2012 Reviewed Reviewer Report - Anja von Heydebreck
20 Dec 2012 Author responded Author comments - Andrew Stein
Resubmission - Version 3
20 Dec 2012 Submitted Manuscript version 3
Publishing
31 Jan 2013 Editorially accepted
2 Apr 2013 Article published 10.1186/1471-2407-13-173

You can find further information about peer review here.

Back to article page